Clinical Trials Browser

Approved for marketing × INDUSTRY × Carcinoma, Non-Small-Cell Lung × Clear all

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Approved for marketing

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

NCT04535557 2022-09-30

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04204928 2021-08-13

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary

NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Approved for marketing

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01931306 2018-11-14

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01649284 2016-11-30

Afatinib Expanded Access Program

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01209650 2016-11-10

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Afatinib Expanded Access Program

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)